Dan Nicolson: ASCO24 features exciting research in liquid biopsy

Dan Nicolson, Director of Biopharma Business Development at Personalis, Inc., recently shared on LinkedIn:

“This year’s annual American Society of Clinical Oncology (ASCO) meeting features exciting research in liquid biopsy.

‘Breast cancer cells can remain in the body after surgery and other treatments but there can be so few of these cells that they are undetectable on follow-up scans,” said Isaac Garcia-Murillas, the study’s lead author at the Institute of Cancer Research (ICR) in London.

Previous research has suggested that ctDNA blood tests can identify relapse before it can be seen on a scan. However, these tests tend to use a technique called whole exome sequencing that typically looks for between 16 and 50 mutations.

The new test by Personalis, Inc. uses whole genome sequencing and searches for 1,800 mutations, making it much more sensitive.”

Read further
Source: Dan Nicolson/LinkedIn